IDH1 and central nervous system cancer: Although the use of LITT in the treatment of grades II and III glioma has increased over the last few decades for both primary [3,4] and recurrent gliomas [24,29], to our knowledge, this is the first multi-patient study analyzing the outcomes of IDH1/2 mutant grade 2/3 gliomas treated with LITT.